BACKGROUND: Treatment of focal hyperhidrosis with botulinum toxin A (BTX-A) is known to be effective in the axillary, palmar, and plantar region. No studies evaluating the treatment of hyperhidrosis in the anal fold with BTX-A are available, however. OBJECTIVE: The objective was to evaluate whether or not injections with BTX-A are an effective therapy option for the treatment of focal hyperhidrosis of the anal fold. MATERIAL AND METHODS: Eleven male patients (median age, 28.3 years) with focal hyperhidrosis of the anal fold as assessed by modified iodine-starch test were enrolled. Each patient received intradermal injections with 38 U on average (30-54 U) of BTX-A (BOTOX, Allergan Inc.). Changes in sweat rates were documented by comparing the size of hyperhidrotic area in square centimeters before and 4 weeks after injection. RESULTS: The mean reduction of hyperhidrotic area was 29.9 cm(2) (range, 27-43 cm(2)), corresponding to a reduction of 78.5%. Apart from painful injections, no side effects were observed. CONCLUSION: BTX-A is an effective therapy for patients with focal hyperhidrosis of the anal fold.
BACKGROUND: Treatment of focal hyperhidrosis with botulinum toxin A (BTX-A) is known to be effective in the axillary, palmar, and plantar region. No studies evaluating the treatment of hyperhidrosis in the anal fold with BTX-A are available, however. OBJECTIVE: The objective was to evaluate whether or not injections with BTX-A are an effective therapy option for the treatment of focal hyperhidrosis of the anal fold. MATERIAL AND METHODS: Eleven male patients (median age, 28.3 years) with focal hyperhidrosis of the anal fold as assessed by modified iodine-starch test were enrolled. Each patient received intradermal injections with 38 U on average (30-54 U) of BTX-A (BOTOX, Allergan Inc.). Changes in sweat rates were documented by comparing the size of hyperhidrotic area in square centimeters before and 4 weeks after injection. RESULTS: The mean reduction of hyperhidrotic area was 29.9 cm(2) (range, 27-43 cm(2)), corresponding to a reduction of 78.5%. Apart from painful injections, no side effects were observed. CONCLUSION: BTX-A is an effective therapy for patients with focal hyperhidrosis of the anal fold.
Authors: Leandra Reguero Del Cura; Marta Drake Monfort; Adrian De Quintana Sancho; Marcos Antonio González López Journal: Skin Appendage Disord Date: 2021-04-28